Mersana Therapeutics

Yahoo Finance • 2 days ago

Halper Sadeh LLC Encourages SEE, EXAS, MRSN Shareholders to Contact the Firm to Discuss Their Rights

NEW YORK, Nov. 27, 2025 (GLOBE NEWSWIRE) -- Halper Sadeh LLC, an investor rights law firm, is investigating the following companies for potential violations of the federal securities laws and/or breaches of fiduciary duties to shareholde... Full story

Yahoo Finance • 2 days ago

HAPPY THANKSGIVING AND ALERT: The M&A Class Action Firm Continues to Investigate the Merger – EXAS, SEE, CDTX, and MRSN

NEW YORK, Nov. 27, 2025 (GLOBE NEWSWIRE) -- We wish you a Happy Thanksgiving and Class Action Attorney Juan Monteverde with Monteverde & Associates PC (the “M&A Class Action Firm”), who has recovered millions of dollars for shareholders... Full story

Yahoo Finance • 15 days ago

Key deals this week: Merck, Day One Biopharmaceutical, ABN AMRO, Revvity, Centerspace and more

Here's a list of key deals reported across sectors this week: Merck (MRK [https://seekingalpha.com/symbol/MRK]) to acquire [https://seekingalpha.com/pr/20307875-merck-to-acquire-cidara-therapeutics-inc-diversifying-its-portfolio-to-includ... Full story

Yahoo Finance • 16 days ago

BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of the Following Investigations: Cidara Therapeutics, Inc. (Nasdaq - CDTX), Mersana Therapeutics, Inc. (Nasdaq - MRSN), TreeHouse Foods Inc. (NYSE - THS), Gulf Island Inc. (Nasdaq - GIFI)

BALA CYNWYD, Pa., Nov. 14, 2025 (GLOBE NEWSWIRE) -- Brodsky & Smith reminds investors of the following investigations. If you own shares and wish to discuss the investigation, contact Jason Brodsky (jbrodsky@brodskysmith.com) or Marc Ack... Full story

Yahoo Finance • 16 days ago

Halper Sadeh LLC Encourages MRSN, THS, HBAN Shareholders to Contact the Firm to Discuss Their Rights

NEW YORK, Nov. 14, 2025 (GLOBE NEWSWIRE) -- Halper Sadeh LLC, an investor rights law firm, is investigating the following companies for potential violations of the federal securities laws and/or breaches of fiduciary duties to shareholde... Full story

Yahoo Finance • 16 days ago

Mersana Therapeutics GAAP EPS of -$1.51 misses by $0.30, revenue of $11M misses by $4.5M

* Mersana Therapeutics press release [https://seekingalpha.com/pr/20307899-mersana-therapeutics-provides-business-update-and-announces-third-quarter-2025-financial] (MRSN [https://seekingalpha.com/symbol/MRSN]): Q3 GAAP EPS of -$1.51 mis... Full story

Yahoo Finance • 16 days ago

Here are the major earnings before the open Friday

Major earnings expected before the bell on Friday include: * HIVE Digital Technologies Ltd. (HIVE [https://seekingalpha.com/symbol/HIVE]) * Bit Digital (BTBT [https://seekingalpha.com/symbol/BTBT]) * Allianz SE (OTCPK:ALIZY [https:/... Full story

Yahoo Finance • 16 days ago

$HAREHOLDER ALERT: The M&A Class Action Firm Announces An Investigation of Mersana Therapeutics, Inc. (NASDAQ: MRSN)

NEW YORK, Nov. 13, 2025 (GLOBE NEWSWIRE) -- ClassAction Attorney Juan Monteverde with Monteverde & Associates PC (the “M&A Class Action Firm”), has recovered millions of dollars for shareholders and is recognized as a Top 50 Firm in the... Full story

Yahoo Finance • 17 days ago

Mersana Therapeutics To Be Acquired By Day One Biopharmaceuticals For Up To $285 Mln

(RTTNews) - Mersana Therapeutics, Inc. (MRSN), a biopharmaceutical company, Thursday, announced that it has entered a definitive agreement to be acquired by Day One Biopharmaceuticals through a tender offer followed by a second step merger... Full story

Yahoo Finance • 17 days ago

Day One to buy Mersana Therapeutics for $25/share upfront

[Antibody drug conjugated with cytotoxic payload.] Love Employee/iStock via Getty Images Day One Biopharmaceuticals (DAWN [https://seekingalpha.com/symbol/DAWN]) has signed a definitive merger agreement to acquire clinical-stage biopharma... Full story

Yahoo Finance • 17 days ago

Day One Biopharmaceuticals to Acquire Mersana Therapeutics

Agreement with Day One Biopharmaceuticals provides for upfront consideration of $25.00 per share in cash, plus potential contingent value rights cash payments of up to an aggregate of $30.25 per share, for aggregate deal value of up to app... Full story

Yahoo Finance • 20 days ago

Mersana Therapeutics to Host Third Quarter 2025 Conference Call on November 14, 2025

CAMBRIDGE, Mass., Nov. 10, 2025 (GLOBE NEWSWIRE) -- Mersana Therapeutics, Inc. (NASDAQ: MRSN), a clinical-stage biopharmaceutical company focused on the development of antibody-drug conjugates (ADCs) targeting cancers in areas of high un... Full story

Yahoo Finance • 4 months ago

Mersana targets reporting initial Emi-Le expansion data in H2 2025 while achieving $15M GSK milestone

Earnings Call Insights: Mersana Therapeutics (MRSN) Q2 2025 MANAGEMENT VIEW * Martin H. Huber, President, CEO & Director, opened by highlighting the progress on Emi-Le, the company's Dolasynthen ADC targeting B7-H4, emphasizing oral pr... Full story

Yahoo Finance • 4 months ago

Form 8K Mersana Therapeutics Inc For: 13 August

... Full story

Yahoo Finance • 4 months ago

Mersana Therapeutics Q2 2025 Earnings Preview

* Mersana Therapeutics (NASDAQ:MRSN [https://seekingalpha.com/symbol/MRSN]) is scheduled to announce Q2 earnings results on Wednesday, August 13th, before market open. The consensus EPS Estimate is -$4.25 [https://seekingalpha.com/symbo... Full story

Yahoo Finance • 4 months ago

Mersana Therapeutics to Host Second Quarter 2025 Conference Call on August 13, 2025

CAMBRIDGE, Mass., Aug. 06, 2025 (GLOBE NEWSWIRE) -- Mersana Therapeutics, Inc. (NASDAQ: MRSN), a clinical-stage biopharmaceutical company focused on the development of antibody-drug conjugates (ADCs) targeting cancers in areas of high un... Full story

Yahoo Finance • 4 months ago

Mersana To Implement 1-for-25 Reverse Stock Split To Regain Nasdaq Compliance

(RTTNews) - Mersana Therapeutics (MRSN) will implement a 1-for-25 reverse stock split effective July 25, 2025, aiming to boost its share price and regain compliance with Nasdaq's minimum bid requirement. Approved by shareholders on June 1... Full story

Yahoo Finance • 4 months ago

Mersana Therapeutics Announces 1-for-25 Reverse Stock Split

CAMBRIDGE, Mass., July 24, 2025 (GLOBE NEWSWIRE) -- Mersana Therapeutics, Inc. (NASDAQ: MRSN), a clinical-stage biopharmaceutical company focused on the development of antibody-drug conjugates (ADCs) targeting cancers in areas of high un... Full story

Yahoo Finance • 6 months ago

Mersana Therapeutics Reports Additional Positive Interim Phase 1 Clinical Data for Emi-Le in Oral Presentation at 2025 ASCO Annual Meeting

31% confirmed ORR (8 responses in 26 evaluable patients) across B7-H4 high tumors at intermediate doses 44% confirmed ORR (7 responses in 16 evaluable patients) in the subset of patients with ≤4 prior lines of therapy CAMBRIDGE, Mass., J... Full story

Yahoo Finance • 6 months ago

Mersana Therapeutics to Present at Upcoming Investor Conferences

CAMBRIDGE, Mass., May 20, 2025 (GLOBE NEWSWIRE) -- Mersana Therapeutics, Inc. (NASDAQ: MRSN), a clinical-stage biopharmaceutical company focused on the development of antibody-drug conjugates (ADCs) targeting cancers in areas of high u... Full story